Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ameluz versus Metvix with daylight photodynamic therapy for actinic keratosis
2015-004382-83Phase 3Completed
- Sponsor
- Biofrontera
- Start
- Mar 2016
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in actinic keratosis (AK) comparing Ameluz + daylight PDT side with Metvix + daylight PDT side (2 arms). Primary endpoint: Total lesion clearance rate. Started Mar 2016; status: completed.
02
Drugs
5-aminolevulinic acidmethyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2015-004382-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004382-83.